Pulmonary Talaromycosis: A Window into the Immunopathogenesis of an Endemic Mycosis.

dc.contributor.author

Narayanasamy, Shanti

dc.contributor.author

Dougherty, John

dc.contributor.author

van Doorn, H Rogier

dc.contributor.author

Le, Thuy

dc.date.accessioned

2021-08-18T18:10:25Z

dc.date.available

2021-08-18T18:10:25Z

dc.date.issued

2021-07-06

dc.date.updated

2021-08-18T18:10:23Z

dc.description.abstract

Talaromycosis is an invasive mycosis caused by the thermally dimorphic saprophytic fungus Talaromyces marneffei (Tm) endemic in Asia. Like other endemic mycoses, talaromycosis occurs predominantly in immunocompromised and, to a lesser extent, immunocompetent hosts. The lungs are the primary portal of entry, and pulmonary manifestations provide a window into the immunopathogenesis of talaromycosis. Failure of alveolar macrophages to destroy Tm results in reticuloendothelial system dissemination and multi-organ disease. Primary or secondary immune defects that reduce CD4+ T cells, INF-γ, IL-12, and IL-17 functions, such as HIV infection, anti-interferon-γ autoantibodies, STAT-1 and STAT-3 mutations, and CD40 ligand deficiency, highlight the central roles of Th1 and Th17 effector cells in the control of Tm infection. Both upper and lower respiratory infections can manifest as localised or disseminated disease. Upper respiratory disease appears unique to talaromycosis, presenting with oropharyngeal lesions and obstructive tracheobronchial masses. Lower respiratory disease is protean, including alveolar consolidation, solitary or multiple nodules, mediastinal lymphadenopathy, cavitary disease, and pleural effusion. Structural lung disease such as chronic obstructive pulmonary disease is an emerging risk factor in immunocompetent hosts. Mortality, up to 55%, is driven by delayed or missed diagnosis. Rapid, non-culture-based diagnostics including antigen and PCR assays are shown to be superior to blood culture for diagnosis, but still require rigorous clinical validation and commercialisation. Our current understanding of acute pulmonary infections is limited by the lack of an antibody test. Such a tool is expected to unveil a larger disease burden and wider clinical spectrum of talaromycosis.

dc.identifier

10.1007/s11046-021-00570-0

dc.identifier.issn

0301-486X

dc.identifier.issn

1573-0832

dc.identifier.uri

https://hdl.handle.net/10161/23595

dc.language

eng

dc.publisher

Springer Science and Business Media LLC

dc.relation.ispartof

Mycopathologia

dc.relation.isversionof

10.1007/s11046-021-00570-0

dc.subject

Cavitation

dc.subject

Effusion

dc.subject

Nodule

dc.subject

Respiratory tract

dc.subject

Talaromyces marneffei

dc.subject

Talaromycosis

dc.title

Pulmonary Talaromycosis: A Window into the Immunopathogenesis of an Endemic Mycosis.

dc.type

Journal article

duke.contributor.orcid

Narayanasamy, Shanti|0000-0002-6667-2868

duke.contributor.orcid

Le, Thuy|0000-0002-3393-6580

pubs.organisational-group

School of Medicine

pubs.organisational-group

Molecular Genetics and Microbiology

pubs.organisational-group

Duke Global Health Institute

pubs.organisational-group

Medicine, Infectious Diseases

pubs.organisational-group

Duke

pubs.organisational-group

Basic Science Departments

pubs.organisational-group

University Institutes and Centers

pubs.organisational-group

Institutes and Provost's Academic Units

pubs.organisational-group

Medicine

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Staff

pubs.publication-status

Published

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Pulmonary Talaromycosis_A Window into the Immunopathogenesis of an Endemic Mycosis_2021.pdf
Size:
644.05 KB
Format:
Adobe Portable Document Format
Description:
Published version